C9492 — Injection, durvalumab, 10 mg
C9492 is a HCPCS Level II code for injection, durvalumab, 10 mg. It belongs to the Outpatient Prospective Payment System section. It was terminated on December 31, 2018 and is not valid on new claims.
This code has been terminated
CMS terminated C9492 on December 31, 2018. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Special coverage instructions apply
There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for C9492
- Long descriptor
- Injection, durvalumab, 10 mg
- Short descriptor
- Injection, durvalumab
- Added
- October 1, 2017
- Terminated
- December 31, 2018
- BETOS
- O1D
- Pricing indicator
- 53 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Statute.
Codes adjacent to C9492
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If C9492 is not quite right, the correct code is very often within a few positions of it.
- C9484Injection, eteplirsen, 10 mgterminated
- C9485Injection, olaratumab, 10 mgterminated
- C9486Injection, granisetron extended release, 0.1 mgterminated
- C9487Ustekinumab, for intravenous injection, 1 mgterminated
- C9488Injection, conivaptan hydrochloride, 1 mg
- C9489Injection, nusinersen, 0.1 mgterminated
- C9490Injection, bezlotoxumab, 10 mgterminated
- C9491Injection, avelumab, 10 mgterminated
- C9493Injection, edaravone, 1 mgterminated
- C9494Injection, ocrelizumab, 1 mgterminated
- C9497Loxapine, inhalation powder, 10 mgterminated
- C9507Plasma, high titer covid-19 convalescent, each unit
- C9600Percutaneous transcatheter placement of drug eluting intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch
- C9601Percutaneous transcatheter placement of drug-eluting intracoronary stent(s), with coronary angioplasty when performed; each additional branch of a major coronary artery (list separately in addition to code for primary procedure)
- C9602Percutaneous transluminal coronary atherectomy, with drug eluting intracoronary stent, with coronary angioplasty when performed; single major coronary artery or branch
- C9603Percutaneous transluminal coronary atherectomy, with drug-eluting intracoronary stent, with coronary angioplasty when performed; each additional branch of a major coronary artery (list separately in addition to code for primary procedure)
Questions about C9492
What is HCPCS code C9492?
C9492 is a HCPCS Level II code for injection, durvalumab, 10 mg. It sits in the Outpatient Prospective Payment System section.
Does Medicare cover C9492?
The CMS HCPCS file marks C9492 as "Special coverage instructions apply". There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
Is C9492 still valid?
No. C9492 was terminated on December 31, 2018 and should not be used on new claims.